Country for PR: United States
Contributor: PR Newswire New York
Saturday, January 09 2021 - 12:31
AsiaNet
Appian Selected by Accenture as a Core Partner in the INTIENT Network for Life Sciences
MCLEAN, Va., Jan. 9, 2021 /PRNewswire-AsiaNet/ --

-- Appian brings low-code speed and automation power to help drive innovation 
in drug discovery and scientific research

Appian (NASDAQ: APPN) today announced that it has joined Accenture's INTIENT 
partner ecosystem as a core partner. The ecosystem is designed to help 
independent software vendors (ISVs) and life science companies integrate more 
effectively to accelerate drug discovery efforts and improve patient outcomes.

The INTIENT Network is an integral part of Accenture's INTIENT Platform that 
enables insights and collaboration across the life sciences enterprise to 
improve productivity, efficiency, and innovation in drug discovery. Accenture 
has partnered with Appian to integrate low-code development into the INTIENT 
platform.

The Appian Low-Code Automation Platform ( 
https://c212.net/c/link/?t=0&l=en&o=3009638-3&h=3776717084&u=https%3A%2F%2Fwww.appian.com%2Fplatform%2F%3Futm_source%3Dreferral%26utm_medium%3Dpress-release%26utm_campaign%3Dlca-2h-2020&a=Appian+Low-Code+Automation+Platform 
) allows enterprises to build applications up to 20x faster than traditional 
code. By providing a single interface that unifies data, process, people and 
the digital workforce, Appian helps organizations improve digital innovation 
and optimize business outcomes. Industry leaders trust Appian to improve 
customer experience, achieve operational excellence, and simplify global risk 
management and compliance.

"We are proud to work with Accenture to jointly support research, innovation, 
and better outcomes for the Life Sciences industry," said Marc Wilson, Founder 
and Senior Vice President of Global Partnerships and Industries at Appian. "Our 
ability to accelerate business processes, unify enterprise data, and simplify 
global compliance is why nine of the world's top 10 drug and biotech 
organizations use Appian." 

As part of the INTIENT partner ecosystem, Appian's platform can be accessible 
across the INTIENT product suites. 

"Our open partner network is one of the ways we're bringing innovation to our 
clients through the Accenture INTIENT Platform," said Jill Schulte, managing 
director in Accenture's Life Sciences practice. "Appian's integration into the 
INTIENT Platform enables low-code workflow creation and management to 
accelerate the building of applications for our clients and ultimately for the 
benefit of their customers and patients."

To learn more about Accenture's INTIENT Platform, go to 
https://www.accenture.com/us-en/services/life-sciences/intient 

To request a free trial of the Appian Low-code Automation Platform, go to 
https://www.appian.com/platform/free-trial/.

About Appian
Appian provides a low-code automation platform that accelerates the creation of 
high-impact business applications. Many of the world's largest organizations 
use Appian applications to improve customer experience, achieve operational 
excellence, and simplify global risk management and compliance. For more 
information, visit www.appian.com. 

SOURCE  Appian


CONTACT: Nicole Greggs, Director of Media Relations, +1 703.260.7868, 
Nicole.Greggs@appian.com